Open AccessDenosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
Author(s) -
Paul D. Miller,
Nicola Pannacciulli,
Jacques P. Brown,
E. J. Czerwiński,
Bettina S. Nedergaard,
Michael A. Bolognese,
Jorge Malouf,
Henry G. Bone,
JeanYves Reginster,
Andrea Singer,
C. Wang,
Rachel B. Wagman,
Steven R. Cummings
Publication year - 2016
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2016-1801
Subject(s) - zoledronic acid , denosumab , medicine , osteoporosis , postmenopausal osteoporosis , postmenopausal women , bone density conservation agents , urology , oncology , bone density , bone mineral
Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom